Compare GPCR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPCR | ICUI |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | 13000 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.0B |
| IPO Year | 2023 | 1995 |
| Metric | GPCR | ICUI |
|---|---|---|
| Price | $29.29 | $157.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | $105.78 | ★ $193.38 |
| AVG Volume (30 Days) | ★ 914.2K | 196.2K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.96 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.44 |
| P/E Ratio | ★ N/A | $83.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.59 | $112.50 |
| 52 Week High | $94.90 | $192.85 |
| Indicator | GPCR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 21.44 | 43.25 |
| Support Level | N/A | $152.02 |
| Resistance Level | $56.63 | $160.22 |
| Average True Range (ATR) | 1.79 | 4.13 |
| MACD | -0.27 | 0.65 |
| Stochastic Oscillator | 7.79 | 53.61 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.